A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1183-1189

  Mease, Philip J ^a   Strand, V ^b   Shalamberidze, L ^c   Dimic, A ^d   Raskina, T ^e   Xu, Li An ^f   Liu, Y ^g   Smith, J ^h  

^a SWEDISH MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c V Tsitlanadze Scientifically Practical Rheumatology Center   (Georgia)

^d Institute of Rehabilitation and Treatment   (Serbia)

^e Internal Disease Dept   (Russian Federation)

^f BRISTOL MYERS SQUIBB   (United States)

^g Global Clinical Research   (United States)

^h Alder Biopharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CHOLESTEROL; CLAZAKIZUMAB; FOLIC ACID; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE;

28 JOINT DISEASE ACTIVITY SCORE; ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING DISORDER; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATTY LIVER; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ANALGESICS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASPIRIN; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HEALTH STATUS; HUMANS; INJECTIONS, INTRAVENOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84862783578     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200704     Document Type: Article

References (50)

1. Müller-Ladner U, Pap T, Gay RE, et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:102-10.
2. Englund M, Jöud A, Geborek P, et al. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford) 2010;49:1563-9.
3. Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.
4. Robinson D Jr, Hackett M, Wong J, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006;22:989-1000. (Pubitemid 43875568)
5. Arnold R, Ranchor AV, Sanderman R, et al. The relative contribution of domains of quality of life to overall quality of life for different chronic diseases. Qual Life Res 2004;13:883-96. (Pubitemid 39005098)
6. Centers for Disease Control. Prevalence of disabilities and associated health conditions among adults - United States, 1999. MMWR Morbidity and Mortality Weekly Report 2001;50:120-5.
7. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8. (Pubitemid 36091647)
8. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65 Suppl 1:S4-10.
9. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993;36:611-22.
10. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26. (Pubitemid 44650950)
11. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985;82:5490-4. (Pubitemid 15012129)
12. Kawano MM, Mihara K, Huang N, et al. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995;85:487-94.
13. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-44. (Pubitemid 18073639)
14. Lotz M, Jirik F, Kabouridis P, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988;167:1253-8.
15. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-9.
16. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
17. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40. (Pubitemid 40189432)
18. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40:1830-5.
19. Kaplanski G, Marin V, Montero-Julian F, et al. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25-9. (Pubitemid 35462110)
20. Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int 2006;26:1096-100. (Pubitemid 44450844)
21. Robak T, Gladalska A, Stepieñ H, et al. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998;7:347-53. (Pubitemid 28552768)
22. Lu ZY, Brochier J, Wijdenes J, et al. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992;22:2819-24.
23. Lu ZY, Brailly H, Wijdenes J, et al. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995;86:3123-31.
24. Genentech, Inc. Actemra Prescribing Information. http://www.actemra.com/ default.aspx (accessed 6 September 2011).
25. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
26. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
27. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
28. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
29. National Cancer Institute. Common Terminology Criteria for Adverse Events. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-40 (accessed 6 September 2011).
30. Strand V, Crawford B, Singh J, et al. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
31. Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009;11:R170.
32. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010;28(3 Suppl 59):S32-40.
33. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
34. Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70:996-1002.
35. Zimmerman HJ. Drug-induced liver disease. In: Hepatotoxicity, the Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott, Williams, and Wilkins 1999:428-33.
36. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
37. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
38. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. (Pubitemid 29063266)
39. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
40. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. (Pubitemid 351563997)
41. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76. (Pubitemid 46768126)
42. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
43. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
44. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
45. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9. (Pubitemid 38725087)
46. Rigas JR, Schuster M, Orlov S V, et al. Efect of ALD518, a humanised anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomised, double-blind safety and efficacy trial. J Clin Oncol 2010;28:7631-7631.
47. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96. (Pubitemid 38802622)
48. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37. (Pubitemid 28053135)
49. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-11. (Pubitemid 36299051)
50. Hashizume M, Yoshida H, Koike N, et al. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 2010;69:741-6.